Tetravalent CYD Dengue Vaccine , 5555 formulation + Tetravalent CYD Dengue Vaccine , 5553 formulation + Tetravalent CYD Dengue Vaccine, 4444 formulation
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dengue Fever
Conditions
Dengue Fever, Dengue Hemorrhagic Fever, Dengue Virus
Trial Timeline
Apr 17, 2008 → Feb 1, 2010
NCT ID
NCT00617344About Tetravalent CYD Dengue Vaccine , 5555 formulation + Tetravalent CYD Dengue Vaccine , 5553 formulation + Tetravalent CYD Dengue Vaccine, 4444 formulation
Tetravalent CYD Dengue Vaccine , 5555 formulation + Tetravalent CYD Dengue Vaccine , 5553 formulation + Tetravalent CYD Dengue Vaccine, 4444 formulation is a phase 2 stage product being developed by Sanofi for Dengue Fever. The current trial status is completed. This product is registered under clinical trial identifier NCT00617344. Target conditions include Dengue Fever, Dengue Hemorrhagic Fever, Dengue Virus.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00617344 | Phase 2 | Completed |
Competing Products
20 competing products in Dengue Fever